Tissue-specific, tumor-selective, replication-competent adenovirus vector for cancer gene therapy

Journal of Virology

Volumn 75, Issue 7, 2001, Pages 3314-3324

  Doronin, K ^a   Kuppuswamy, M ^a   Toth, K ^a   Tollefson, A E ^a   Krajcsi, P ^a   Krougliak, V ^a   Wold, W S M ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS DNA; VIRUS PROTEIN; VIRUS VECTOR;

ADENOVIRUS; ARTICLE; BRONCHUS CANCER; CANCER; CANCER CELL; CANCER CELL CULTURE; CELL DIVISION; CYTOLYSIS; GENE DELETION; GENE REPLICATION; GENE THERAPY; HUMAN; HUMAN CELL; LUNG ALVEOLUS CELL TYPE 2; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROMOTER REGION; TISSUE SPECIFICITY;

ADENOVIRUS E1A PROTEINS; ADENOVIRUS E4 PROTEINS; ADENOVIRUSES, HUMAN; ANIMALS; DNA REPLICATION; GENE THERAPY; GENETIC VECTORS; HUMANS; MICE; NEOPLASMS; ORGAN SPECIFICITY; PROMOTER REGIONS (GENETICS); TUMOR CELLS, CULTURED; VIRUS REPLICATION;

EID: 0035100867     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.75.7.3314-3324.2001     Document Type: Article

References (70)

1. Replicative adenoviruses for cancer therapy
2. Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection
3. An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3
4. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells
5. The lung-specific surfactant protein B gene promoter is a target for thyroid transcription factor 1 and hepatocyte nuclear factor 3. Indicating common factors for organ-specific gene expression along the foregut axis
6. Cis-active elements controlling lung cell-specific expression of human pulmonary surfactant protein B gene
7. In vivo and ex vivo gene therapy strategies to treat tumors using adenovirus gene transfer vectors
8. Tumor-specific, replication-competent adenovirus vectors overexpressing the adenovirus death protein
9. Adenovirus replication is coupled with the dynamic properties of the PML nuclear structure
10. A novel three-pronged approach to kill cancer cells selectively: Concomitant viral, double suicide gene, and radiotherapy
11. E1B 55-kilodalton-associated protein: A cellular protein with RNA-binding activity implicated in nucleocytoplasmic transport of adenovirus and cellular mRNAs
12. Phase I trial of recombinant adenovirus gene transfer in lung cancer
13. A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer
14. Cis-acting induction of adenovirus transcription
15. p53 status does not determine outcome of E1B 55-kilodalton mutant adenovirus lytic infection
16. A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma
17. p53-independent and -dependent requirements for E1B-55K in adenovirus type 5 replication
18. Monoclonal antibodies specific for adenovirus early region 1A proteins: Extensive heterogeneity in early region 1A products
19. Targeting the replication of adenoviral gene therapy vectors to lung cancer cells: The importance of the adenoviral E1B-55kD gene
20. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents
21. Intravenous administration of ONYX-015. A selectively replicating adenovirus, induces antitumoral efficacy
22. The discovery and development of selectively replicating adenoviruses as anticancer agents
23. RNA-binding activity of the E1B 55-kilodalton protein from human adenovirus type 5
24. Adenoviruses
25. Retinoblastoma growth suppressor and a 300-kDa protein appear to regulate cellular DNA synthesis
26. ONYX-015: Clinical data are encouraging
27. Development of cell lines capable of complementing E1, E4, and protein IX defective adenovirus type 5 mutants
28. E4 gene function in adenovirus, adenovirus vector and adeno-associated virus infections
29. Corepressor required for adenovirus E1B 55.000-molecular-weight protein repression of basal transcription
30. Adenovirus E1B 55K represses p53 activation in vitro
31. Transcriptional targeting
32. Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy
33. Effective gene therapy for pancreatic cancer by cytokines mediated by restricted replication-competent adenovirus
34. Persistence of recombinant adenovirus in vivo is not dependent on vector DNA replication
35. Transforming potential of the adenovirus type 5 E4orf3 protein
36. Regulation of p53 levels by the E1B 55-kilodalton protein and E4orf6 in adenovirus-infected cells
37. The annual report to the nation on the status of cancer. 1973-1997. With a special section on colorectal cancer
38. Prostate attenuated replication competent adenovirus (ARCA) CN706: A selective cytotoxic for prostate-specific antigen-positive prostate cancer cells
39. In vivo antitumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy
40. Double suicide gene therapy augments the antitumor activity of a replication-competent lytic adenovirus through enhanced cytotoxicity and radiosensitization
41. Inactivation of p53 but not p73 by adenovirus type 5 E1B 55-kilodalton and E4 34-kilodalton oncoproteins
42. Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells
43. Adenovirus E1B-58kd tumor antigen and SV40 large tumor antigen are physically associated with the same 54 kd cellular protein in transformed cells
44. The E3-11.6K protein of adenovirus is an Asn-glycosylated integral membrane protein that localizes to the nuclear membrane
45. Cellular components interact with adenovirus type 5 minimal DNA packaging domains
46. Adenoviridae: The viruses and their replication
47. Modulation of the specificity and activity of a cellular promoter in an adenoviral vector
48. Highly augmented cytopathic effect of a fiber-mutant E1B-defective adenovirus for gene therapy of gliomas
49. The large E1B protein together with the E4orf6 protein target p53 for active degradation in adenovirus infected cells
50. Regulation of apoptosis by viral gene products
51. Preparation and titration of CsCl-banded adenovirus stocks
52. The E3-11.6kDa adenovirus death protein (ADP) is required for efficient cell death: Characterization of cells infected with adp mutants
53. The adenovirus death protein (E3-11.6K) is required at very late stages of infection for efficient cell lysis and release of adenovirus from infected cells
54. w protein encoded by region E3 of adenovirus is expressed early but is greatly amplified at late stages of infection
55. The replicative capacities of large E1B-null group A and group C adenoviruses are independent of host cell p53 status
56. p53 selective and nonselective replication of an E1B-deleted adenovirus in hepatocellular carcinoma
57. Regulation of apoptosis by adenovirus E1A and E1B oncogenes
58. Targeting adenovirus
59. E1B 55-kilodalton oncoproteins of adenovirus types 5 and 12 inactivate and relocalize p53, but not p51 or p73, and cooperate with E4orf6 proteins to destabilize p53
60. Therapy of colon cancer with oncolytic adenovirus is enhanced by the addition of herpes simplex virus-thymidine kinase
61. Adenoviral vectors capable of replication improve the efficacy of HSVtk/GCV suicide gene therapy of cancer
62. Adenovirus proteins that regulate apoptosis
63. Immune responses to adenoviruses: Viral evasion mechanisms and their implications for the clinic
64. Upstream enhancer activity in the human surfactant protein B gene is mediated by thyroid transcription factor 1
65. Adenovirus-mediated wild-type p53 expression induces apoptosis and suppresses tumorigenesis of prostatic tumor cells
66. Inhibition of p53 transactivation required for transformation by adenovirus early 1B protein
67. Adenovirus E1B oncoprotein tethers a transcriptional repression domain to p53
68. ONYX-015 works synergistically with chemotherapy in lung cancer cell lines and primary cultures freshly made from lung cancer patients
69. The addition of adenovirus type 5 region E3 enables Calydon virus 787 to eliminate distant prostate tumor xenografts
70. Identification of the transcriptional regulatory sequences of human kallikrein 2 and their use in the construction of Calydon virus 764, an attenuated replication competent adenovirus for prostate cancer therapy